ASPET

SEPTEMBER 16, 2024

GBM has a poor prognosis despite aggressive treatment, in part due to lack of adequate drug permeability at the BBB. Standard of care GBM therapies include radiation and cytotoxic chemotherapy that lead to DNA damage. These observations can guide further exploration of elimusertib for the treatment of GBM, or other CNS tumors.

Pharmacogenetics 100

Pharmacogenetics DNA Pharmacokinetics Treatment 100

ASPET

JUNE 10, 2024

Radiation therapy, a standard treatment option for many cancer patients, induces DNA double strand breaks (DSBs), leading to cell death. This approach will provide critical insights for the clinical translation of WSD0628 for the treatment of primary and secondary brain tumors.

Pharmacokinetics 100

Pharmacokinetics Pharmacogenetics Treatment DNA 100

ASPET

OCTOBER 12, 2023

With this in mind, a major challenge in developing therapies for central nervous system (CNS) tumors is to overcome barriers to delivery, including the blood-brain barrier (BBB). Simulation using a compartmental BBB model suggests inadequate exposure of free panobinostat in the brain following a recommended oral dosing regimen in patients.

Pharmacogenetics 100

Pharmacogenetics Clinical Trials Treatment Therapies 100

The Pharma Data

OCTOBER 27, 2020

Collaborators today include Synlab, PathGroup (US), SRL Diagnostics (Asia), Fundación Jimenez Díaz, The Royal Marsden NHS Foundation Trust, Istituto Nazionale Tumori Regina Elena Roma and Diatech Pharmacogenetics (EU). There is a better way to get every patient the treatment they deserve. We believe that DXRX is that way.

Pharmacogenetics 40

Pharmacogenetics Laboratories Therapies Hospitals 40